Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | TGM2 | P21980 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3728729 | 0.95 | HTT (0.70) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL4159934 | 0.94 | TGM2 (0.72) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9779379 | 0.94 | TGM2 (0.72) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL12487959 | 0.94 | TGM2 (0.72) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL1415897 | 0.90 | LMNA (0.71) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL18254066 | 0.90 | HTT (0.81) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL15346534 | 0.88 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9340146 | 0.88 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9874334 | 0.88 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL13055383 | 0.86 | LMNA (0.80) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | claimed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | claimed |
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | CYTOKINETICS, INC. | 2009-09-03 | — | — | US | claimed |
| EP-1786265-A4 | NOVEL COMPOSITIONS AND METHODS OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2009-08-19 | — | — | EP | claimed |
| EP-1773348-A4 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS INC (US) | 2009-05-20 | — | — | EP | claimed |
| US-7528137-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2009-05-05 | — | — | US | claimed |
| US-7482343-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2009-01-27 | — | — | US | claimed |
| US-7476743-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2009-01-13 | — | — | US | claimed |
| US-7439254-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2008-10-21 | — | — | US | claimed |
| EP-1692112-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-09-24 | — | — | EP | claimed |
| EP-0491053-A1 | WATER-SOLUBLE BIS-DIOXOPIPERAZINE DERIVATIVES WITH ANTITUMORAL PROPERTIES | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1992-06-24 | — | — | EP | claimed |
| EP-0473337-A2 | Nor-statine and nor-cyclostatine polypeptides in the treatment of ocular hypertension and glaucoma | PFIZER INC. (US) | 1992-03-04 | — | — | EP | claimed |
| US-5036104-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1991-07-30 | — | — | US | claimed |
| US-5034376-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1991-07-23 | — | — | US | claimed |
| EP-0428849-A2 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | claimed |
| US-4935405-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1990-06-19 | — | — | US | claimed |
| EP-0119954-B1 | 3-AMINO-1-BENZAZEPIN-2-ONE-1-ALCANOIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR PHARMACEUTICAL PREPARATION AS WELL AS THEIR THERAPEUTIC USE | CIBA-GEIGY AG (CH) | 1990-03-14 | — | — | EP | claimed |
| EP-0266950-A2 | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1988-05-11 | — | — | EP | claimed |
| US-4591459-A | Intermediates for 6-(aminoacyloxymethyl) penicillanic acid 1,1-dioxides | PFIZER INC. (US) | 1986-05-27 | — | — | US | claimed |
| EP-0119954-A2 | 3-Amino-1-benzazepin-2-one-1-alcanoic acids, process for their preparation, their pharmaceutical preparation as well as their therapeutic use | CIBA-GEIGY AG (CH) | 1984-09-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221488-A1 | Certain Compositions and Methods of Treatment | TOP2A, TOP2B, TOP1 | HTT 2056/4885TGM2 2718/4885LMNA 1960/4885 |
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | HTT 969/4885TGM2 455/4885LMNA 2061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.